Moteur de recherche d’entreprises européennes

Financement de l’UE (6 000 000 €) : Préférences des patients dans l’évaluation des bénéfices-risques au cours du cycle de vie du médicament - Sofia réf. : 115966 Hor 01/10/2016 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Préférences des patients dans l’évaluation des bénéfices-risques au cours du cycle de vie du médicament - Sofia réf. : 115966

The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i.e. in the early stages of identifying medical needs, in clinical testing, to guide decisions on reimbursement and to make decisions on withdrawal of drugs from the market. A broad array of (combinations of) patient preference methods will be tested prospectively in a large number of case studies. The availability of large patient cohorts will enable to test new methods or deviations from existing methods in a randomized manner, by comparing well-known methods with newer ones. The use of simulation studies will both contribute to smarter design of case studies and to exploring the sensitivity of outcomes of preference studies. Based on discussions with a broad representation of stakeholders e.g. patients, patient organisations, regulatory authorities, HTA bodies and reimbursement agencies, suitable methods will be tested and their contributions to improved decision making will be discussed in recommendations adapted to the needs of all relevant stakeholders. The recommendations from PREFER are expected to lead to changed practices, in that industry will routinely assess whether a preference study would add value at key decision points in the medicinal product life cycle and, if so, implement patient-preference elicitation studies according to the PREFER project recommendations. The PREFER consortium consist of 16 industry partners and 16 academic and SME members including representation from academia, patient organizations, HTA bodies, reimbursement agencies, and project management.


AbbVie Ltd. 0,00 €
Actelion Pharmaceuticals Ltd. 0,00 €
Amgen Ltd. 0,00 €
Astellas Pharma Europe B.V. 0,00 €
Astrazeneca AB 0,00 €
Bayer AG 0,00 €
Bayer Pharma AG 0,00 €
Centre Federal d'Expertise des Soins de Sante 252 500 €
Collaborate Project Management GmbH 282 500 €
CSL Behring GmbH 0,00 €
Eli Lilly and Company Ltd. 0,00 €
Erasmus Universitair Medisch Centrum Rotterdam 22 513 €
Erasmus Universiteit Rotterdam 782 257 €
European Cancer Patient Coalition 223 250 €
F. Hoffmann-LA Roche AG 0,00 €
Forum des Patients Europeens 65 000 €
Instituto Tumori Giovanni Paolo II Irccs 25 783 €
International Alliance of Patient'Organizations 63 173 €
International Strategic Marketing Services (Isms) 0,00 €
Istituto Europeo Di Oncologia Srl 496 750 €
Janssen Pharmaceutica N.V. 0,00 €
Katholieke Universiteit Leuven 772 759 €
Merck KGaA 0,00 €
Merck Sharp & Dohme Corp 0,00 €
Mindbytes 259 937 €
Muscular Dystrophy Group of Great Britain and Northern Ireland 80 000 €
Novartis Pharma AG 0,00 €
Pfizer Ltd. 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
Takeda Development Centre Europe Ltd. 0,00 €
Takeda Pharmaceuticals International AG 0,00 €
The University of Birmingham 241 750 €
Universitair Medisch Centrum Utrecht 480 517 €
Universitatsklinikum Erlangen 230 722 €
University of Newcastle Upon Tyne 264 922 €
Uppsala Universitet 1 455 667 €

https://cordis.europa.eu/project/id/115966

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.